Advertisement


David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

Advertisement

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.



Related Videos

Lymphoma

Jonathon Cohen, MD, on Deferring MCL Treatment

Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).

Lymphoma

Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results

Andrew J. Davies, MRCP, PhD, of the Cancer Research UK Centre, University of Southampton, discusses a study of targeted treatment for diffuse large B-cell lymphoma based on real-time gene-expression profiling (Abstract 812).

Leukemia

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Lymphoma

Ronald Go, MD, on Survival in NHL and Treatment Facility Volume

Ronald Go, MD, of the Mayo Clinic, discusses a study that used the National Cancer Data Base to determine the extent to which the number of non-Hodgkin lymphoma patients treated annually in a facility affects overall survival (Abstract 266).

Advertisement

Advertisement




Advertisement